Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 773-779

  Iwamoto, Jun ^a   Miyata, Atsushi ^b   Sato, Yoshihiro ^c   Takeda, Tsuyoshi ^a   Matsumoto, Hideo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yahata Clinic   (Japan)

^c Mitate Hospital   (Japan)

Author keywords

Alendronate; Osteopenia; Osteoporosis; Postmenopausal women; Risk factors for fractures

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CREATININE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FRACTURE; HUMAN; JAPANESE; METACARPAL BONE; OSTEOPENIA; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; VERTEBRA FRACTURE;

EID: 77949469769     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
3. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;23(1):CD001155.
4. The WHO Scientif ic Group. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003;921:86-109.
5. Orimo H, Shiraki M, Hayashi Y, et al. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int. 1994;54:370-376.
6. Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis:a randomized, double-blind, active-controlled, double-dummy trial. Current Therapeutic Research. 2002;63:9:606-620.
7. Kushida K, Shiraki M, Nakamura T, et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab. 2004;22:462-468.
8. Bone HG, Hosking D, Devogelaer JP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
9. Orimo H. Japanese guideline for prevention and treatment of osteoporosis. Life Science. 2006.
10. Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab. 1998;16:139-150.
11. Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001;19:331-337.
12. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int. 1999;10:183-192.
13. Uchida S, Taniguchi T, Shimizu T, et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab. 2005;23:382-388.
14. Iwamoto J, Takeda T, Sato Y, Uzawa M. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with one-year response of lumbar bone mineral density to alendronate in Japanese postmenopausal women with osteoporosis. J Bone Miner Metab. 2005;23:238-242.
15. Nishizawa Y, Nakamura T, Ohta H, et al; Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab. 2005;23:97-104.
16. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
17. Iwamoto J, Takeda T, Sato Y, et al. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol. 2004;23:383-389.
18. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med. 1996;101:488-501.
19. Shiraki M, Fukuchi M, Kiriyama T, et al. Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis. J Bone Miner Metab. 2004;22:352-359.
20. 3. Bone Miner. 1993;20:223-234.